AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital.
Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness in additional autoimmune diseases.
AbolerIS’ lead programme is a monoclonal antibody against CD45RC, a novel molecular target expressed on a subset of T cells that acts upstream of anti-inflammatory cytokine effectors.
The therapy works by eliminating autoreactive effector T cells, increasing the relative ratio of regulatory T cells (Tregs), sparing memory T cells, and inducing immune tolerance.
It has the potential for being a first-in-class molecule addressing the needs of a significant number of rheumatoid arthritis patients, refractory to the current standard of care treatment (anti-TNFs), which is a multi-billion dollar franchise.
Dr Ignacio Anegon and Dr Carole Guillonneau, Co-Founders of AbolerIS Pharma said: “By targeting pathogenic CD45RC-expressing cells and harnessing the power of regulatory T cells, this therapy aims to restore immune balance and target the underlying causes of these diseases, offering the hope of long-lasting remission and a reduced reliance on immune-suppressing medications.”
